Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Launched by PROGEN PHARMACEUTICALS · Jun 25, 2008

Keywords

ClinConnect Summary

This study will use a dose escalation design to determine the MTD of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7 treatment arms. The dose of CGC-11047 will be escalated in cohorts of 3 patients and dose escalation can proceed in each treatment group independent of dose escalation in the other treatment groups. CGC-11047 will be administered IV over 60 minutes and the doses of gemcitabine, docetaxel, bevacizumab, cisplatin, 5-flurouracil or sunitinib will remain fixed accord...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • non-hematological advanced solid tumor malignancy or lymphoma where no curative therapy exists in which monotherapy with gemcitabine or docetaxel or bevacizumab or erlotinib or cisplatin, or 5-flurouracil or sunitinib would otherwise be warranted.
• • measurable disease based on radiographic evaluation or elevated tumor markers.
• • ECOG - 0 or 1 (KPS \>70).
• • Life expectancy \> 3 months.
• Exclusion Criteria:
• • chemotherapy within 21 days or radiotherapy within 4 weeks prior to entering the study
• • known active brain metastases or leptomeningeal carcinomatosis.
• • history of a myocardial infarction within the prior 6 months or, hospitalizations for congestive heart failure within the prior 6 months, or active treatment for uncontrolled cardiac arrhythmias
• • clinically significant gastrointestinal tract hemorrhage, requiring transfusion therapy, within the prior 3 months.